The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Extracranial palliative radiotherapy for metastatic renal cell carcinoma.
 
Young Suk Kwon
No Relationships to Disclose
 
Eric Hsu
No Relationships to Disclose
 
Maggie Stein
Research Funding - The University of North Texas Health Science Center
 
Alana Christie
No Relationships to Disclose
 
Aurelie Garant
Research Funding - Reflexion Medical (Inst); Teleflex Medical
 
Andrew Zhuang Wang
No Relationships to Disclose
 
Daniel X. Yang
No Relationships to Disclose
 
Allen Yen
No Relationships to Disclose
 
Mihailo Miljanic
No Relationships to Disclose
 
Kevin Dale Courtney
Stock and Other Ownership Interests - Regeneron (I)
Consulting or Advisory Role - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene/Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Lilly (Inst); Myovant Sciences (Inst); Novartis (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Surface Oncology (Inst)
Patents, Royalties, Other Intellectual Property - My spouse receives patent royalties from Athena Diagnostics, Inc. (I)
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; MJH Life Sciences; Pacific Genuity; Peerview
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; Exelixis; Janssen; Lilly; Merck; Pfizer; QED Therapeutics; Sanofi/Aventis; Seagen
Research Funding - Astellas Pharma; Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Pfizer (Inst); Regeneron (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Waddah Arafat
Consulting or Advisory Role - Seagen
Research Funding - AstraZeneca (Inst); Basilea (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst)
 
Qian Qin
No Relationships to Disclose
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Procept Biorobotics
 
James Brugarolas
Consulting or Advisory Role - Eisai; Exelixis; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Patent of HIF-2 biomarker; Patent pertaining HIF2a resistance mutations; U.S. patent application No. 17/153,128 "PET Radiopharmaceuticals for Non-invasive Evaluation of HIF-2alpha"
 
Robert D. Timmerman
Leadership - CHAIR
Research Funding - principal investigator
 
Raquibul Hannan
No Relationships to Disclose